Sam Brusco, Associate Editor03.15.21
NAMSA, a medical device-focused contract research organization (CRO) appointed Dr. Christophe Berthoux as NAMSA’s new CEO, effective March 22. Dr. Berthoux was most recently CEO of Synexus Clinical Research Limited and is currently an operating partner of private equity healthcare firm, ArchiMed, which acquired majority stake in NAMSA last September.
Former president and CEO John Gorski will relinquish day-to-day operations to focus on strategy and serve as the Vice Chair of NAMSA’s Board of Directors.
Commenting on this change, Gorski stated to the press, “Although my desire is to step down as CEO after fully committing 15 years as its leader, my heart is with NAMSA and I will continue to be involved in a meaningful way. Dr. Berthoux possesses the expertise and vision for NAMSA’s future goals, and has the talent and drive to lead us forward. I look forward to working more closely with our Board of Directors to provide support to Christophe as he builds upon NAMSA’s marketplace position as the CRO leader in the medical device industry,” Gorski concluded.
“I am thrilled to be joining NAMSA’s global team,” Christophe said. “I believe NAMSA has a great business model and talented management team that uniquely positions it to capitalize on the dynamic medtech development environment. As the industry continues to look for trusted partners to enable the development of life-saving technologies, I believe NAMSA is leading the way in providing robust and proven development solutions for Sponsors across the globe,” Berthoux concluded.
Nadim Yared has also been appointed as NAMSA’s new Board of Directors Chairman. Yared, previously serving as president and CEO of medical device firm CVRx and Chairman of AdvaMed, developed and commercialized the world’s first neuromodulation device to treat chronic heart failure (BAROSTIM NEO).
Denis Ribon, ArchiMed’s Chairman commented, “These leadership appointments solidify the aggressive growth strategy we have put in motion at NAMSA. We have much to gain from these transitions, as do global Sponsors as we provide them with proven solutions to achieve cost-effective, efficient commercialization of innovative medical technologies. Together, we will make an even greater impact on patient outcomes and advancing healthcare worldwide,” Ribon concluded.
Former president and CEO John Gorski will relinquish day-to-day operations to focus on strategy and serve as the Vice Chair of NAMSA’s Board of Directors.
Commenting on this change, Gorski stated to the press, “Although my desire is to step down as CEO after fully committing 15 years as its leader, my heart is with NAMSA and I will continue to be involved in a meaningful way. Dr. Berthoux possesses the expertise and vision for NAMSA’s future goals, and has the talent and drive to lead us forward. I look forward to working more closely with our Board of Directors to provide support to Christophe as he builds upon NAMSA’s marketplace position as the CRO leader in the medical device industry,” Gorski concluded.
“I am thrilled to be joining NAMSA’s global team,” Christophe said. “I believe NAMSA has a great business model and talented management team that uniquely positions it to capitalize on the dynamic medtech development environment. As the industry continues to look for trusted partners to enable the development of life-saving technologies, I believe NAMSA is leading the way in providing robust and proven development solutions for Sponsors across the globe,” Berthoux concluded.
Nadim Yared has also been appointed as NAMSA’s new Board of Directors Chairman. Yared, previously serving as president and CEO of medical device firm CVRx and Chairman of AdvaMed, developed and commercialized the world’s first neuromodulation device to treat chronic heart failure (BAROSTIM NEO).
Denis Ribon, ArchiMed’s Chairman commented, “These leadership appointments solidify the aggressive growth strategy we have put in motion at NAMSA. We have much to gain from these transitions, as do global Sponsors as we provide them with proven solutions to achieve cost-effective, efficient commercialization of innovative medical technologies. Together, we will make an even greater impact on patient outcomes and advancing healthcare worldwide,” Ribon concluded.
